Beneficial effects of naringenin in liver diseases: Molecular mechanisms

Nutritional status in patients with liver cirrhosis

Aim of the study

To evaluate the nutritional status in patients with liver cirrhosis, depending on the stage of the disease. Fatty body mass, lean body mass and fluid content were determined, as well as basal metabolic rate.

Material and methods

The study included 56 patients with liver cirrhosis, aged 54 ±12 years. Nutritional status was determined with the BMI and albumin serum concentration. Fatty body mass, lean body mass and fluid content, as well as basal metabolic rate, were estimated by bioelectrical impedance, using a MALTRON 907 analyzer.

Results

Based on albumin concentration, malnutrition was diagnosed in over 80% of patients, usually (100%) in patients with liver cirrhosis belonging to Child-Pugh class C. In all patients, high energy demand was found in relation to basal metabolic rate. Average fatty body mass was comparable in all patients and ranged from 24 to 30%. Fluid content in the tissues was comparable in all evaluated groups and did not correlate with accompanying ascites. Fluid excess was found in 25% of Child-Pugh class A patients, in 59% of class B patients and in 60% of class C patients.

Conclusions

Malnutrition is present in over 80% of patients with liver cirrhosis, and its frequency correlates with the stage of liver insufficiency. Patients with liver cirrhosis show high energy demand for basal metabolic processes. Fluid excess is mainly found in patients with more severe liver injury, but it does not correlate directly with ascites.

A novel screening method for potential naringinase-producing microorganisms

Naringinase has high industrial importance, and the progress in naringinase research is still quite slow. The unavailability of an effective, simple screening method, which will be applicable to different microorganisms such as bacteria, fungi, and actinomycetes, is one of the main reasons for this gap. Therefore, a simple plate assay was developed for effective screening of microorganisms for naringinase by exposing to iodine vapors. This plate assay will fill the technological void for simple screening method and will lead to screen more potent industrially important naringinase-producing microorganisms.

The Therapeutic Potential of Naringenin: A Review of Clinical Trials

Naringenin is a flavonoid belonging to flavanones subclass. It is widely distributed in several Citrus fruits, bergamot, tomatoes and other fruits, being also found in its glycosides form (mainly naringin). Several biological activities have been ascribed to this phytochemical, among them antioxidant, antitumor, antiviral, antibacterial, anti-inflammatory, antiadipogenic and cardioprotective effects. Nonetheless, most of the data reported have been obtained from in vitro or in vivo studies. Although some clinical studies have also been performed, the main focus is on naringenin bioavailability and cardioprotective action. In addition, these studies were done in compromised patients (i.e., hypercholesterolemic and overweight), with a dosage ranging between 600 and 800 μM/day, whereas the effect on healthy volunteers is still debatable. In fact, naringenin ability to improve endothelial function has been well-established. Indeed, the currently available data are very promising, but further research on pharmacokinetic and pharmacodynamic aspects is encouraged to improve both available production and delivery methods and to achieve feasible naringenin-based clinical formulations.

Recent Trends in Potential Therapeutic Applications of the Dietary Flavonoid Didymin

Didymin (isosakuranetin 7-O-rutinoside) is an orally bioactive dietary flavonoid glycoside first found in citrus fruits. Traditionally, this flavonoid has long been used in Asian countries as a dietary antioxidant. Recent studies have provided newer insights into this pleiotropic compound, which could regulate multiple biological activities of many important signaling molecules in health and disease. Emerging data also presented the potential therapeutic application of dietary flavonoid glycoside didymin against cancer, neurological diseases, liver diseases, cardiovascular diseases, and other diseases. In this review, we briefly introduce the source and extraction methods of didymin, and summarize its potential therapeutic application in the treatment of various diseases, with an emphasis on molecular targets and mechanism that contributes to the observed therapeutic effects. The dietary flavonoid didymin can be used to affect health and disease with multiple therapeutic targets, and it is anticipated that this review will stimulate the future development of this potential dietary medicine.

Antioxidative effect of flavonoid naringenin in the lenses of type 1 diabetic rats

Oxidative stress arising during diabetes may lead to cataract formation. Thus, in order to prevent oxidative stress development, antioxidants could be considered helpful agents. Naringenin, a flavonoid with a well-documented antioxidative activity, can be found in many plant-derived products, especially citrus fruits. The aim of the study was to examine the effect of naringenin on oxidative stress markers in the lenses of type 1 diabetic rats. The study was conducted on 3-month-old male Wistar rats with streptozotocin-induced type 1 diabetes. The rats were treated orally with naringenin at the doses of 50 and 100 mg/kg for 4 weeks. In the lenses obtained from the animals, enzymatic and non-enzymatic parameters connected with oxidative stress were measured. The enzymatic parameters included superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glucose-6-phosphate dehydrogenase activity. For non-enzymatic parameters, the total thiol groups, reduced and oxidized glutathione, protein carbonyl groups, advanced oxidation protein products, malondialdehyde and vitamin C level were assayed. Oral administration of naringenin counteracted most of the unfavorable changes induced by diabetes, including reduction of elevated antioxidative enzymes activity and amelioration of oxidative damage in proteins and lipids. Naringenin administered orally reduces oxidative stress markers in the lenses of type 1 diabetic rats.

Role of secretory clusterin in hepatocarcinogenesis

Secretory clusterin (sCLU) is a small stress-induced cytoprotective chaperone protein. Its biological functions are similar to those of a heat-shock protein. The sCLU plays a crucial role in cell proliferation, multiple drug resistance, metastasis, and tumor progression. Abnormal sCLU expression in tumor tissues or sera of patients with primary hepatic cancer has been considered a useful biomarker for diagnosis and surveillance. However, the exact relationship between sCLU overexpression and malignant transformation of hepatocytes is still unknown. The present review examines some novel advances of the knowledge about the oncogenic role of sCLU in hepatocarcinogenesis.

New insights into TGF-β/Smad signaling in tissue fibrosis

Transforming growth factor-β1 (TGF-β1) is considered as a crucial mediator in tissue fibrosis and causes tissue scarring largely by activating its downstream small mother against decapentaplegic (Smad) signaling. Different TGF-β signalings play different roles in fibrogenesis. TGF-β1 directly activates Smad signaling which triggers pro-fibrotic gene overexpression. Excessive studies have demonstrated that dysregulation of TGF-β1/Smad pathway was an important pathogenic mechanism in tissue fibrosis. Smad2 and Smad3 are the two major downstream regulator that promote TGF-β1-mediated tissue fibrosis, while Smad7 serves as a negative feedback regulator of TGF-β1/Smad pathway thereby protects against TGF-β1-mediated fibrosis. This review presents an overview of the molecular mechanisms of TGF-β/Smad signaling pathway in renal, hepatic, pulmonary and cardiac fibrosis, followed by an in-depth discussion of their molecular mechanisms of intervention effects both in vitro and in vivo. The role of TGF-β/Smad signaling pathway in tumor or cancer is also discussed. Additionally, the current advances also highlight targeting TGF-β/Smad signaling pathway for the prevention of tissue fibrosis. The review reveals comprehensive pathophysiological mechanisms of tissue fibrosis. Particular challenges are presented and placed within the context of future applications against tissue fibrosis.